Industry Analysts Just Made A Sizeable Upgrade To Their Tango Therapeutics, Inc. (NASDAQ:TNGX) Revenue Forecasts
Industry Analysts Just Made A Sizeable Upgrade To Their Tango Therapeutics, Inc. (NASDAQ:TNGX) Revenue Forecasts
Tango Therapeutics, Inc. (NASDAQ:TNGX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to next year's forecasts. The revenue forecast for next year has experienced a facelift, with analysts now much more optimistic on its sales pipeline. The stock price has risen 8.9% to US$8.94 over the past week, suggesting investors are becoming more optimistic. Whether the upgrade is enough to drive the stock price higher is yet to be seen, however.
Tango Therapeutics, Inc.(納斯達克股票代碼:TNGX)的股東今天將有理由微笑,分析師大幅上調了明年的預測。明年的收入預測有所改觀,分析師現在對其銷售渠道更加樂觀。過去一週,股價上漲8.9%,至8.94美元,這表明投資者變得更加樂觀。但是,升級是否足以推動股價上漲還有待觀察。
After the upgrade, the consensus from Tango Therapeutics' five analysts is for revenues of US$32m in 2024, which would reflect a noticeable 6.0% decline in sales compared to the last year of performance. Losses are supposed to balloon 29% to US$1.36 per share. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$28m and losses of US$1.44 per share in 2024. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a sizeable increase to their revenue forecasts while also reducing the estimated loss as the business grows towards breakeven.
上調後,Tango Therapeutics的五位分析師一致認爲,2024年的收入爲3200萬美元,這將反映銷售額與去年業績相比明顯下降6.0%。虧損預計將激增29%,至每股1.36美元。然而,在最新估計之前,分析師一直預測2024年的收入爲2,800萬美元,每股虧損1.44美元。因此,在最近的共識更新之後,人們的看法發生了很大變化,隨着業務向盈虧平衡的發展,分析師大幅提高了收入預期,同時也減少了估計的虧損。
Check out our latest analysis for Tango Therapeutics
查看我們對 Tango Therapeutics 的最新分析
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20231109/0-ebfdcfcdd4144a9e8a3bb84de7908160-0-0cf38ffd3a3f71998ff96a54a1ac81d9.png/big)
One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. These estimates imply that sales are expected to slow, with a forecast annualised revenue decline of 4.9% by the end of 2024. This indicates a significant reduction from annual growth of 40% over the last year. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 15% annually for the foreseeable future. It's pretty clear that Tango Therapeutics' revenues are expected to perform substantially worse than the wider industry.
獲取有關這些預測的更多背景信息的一種方法是研究它們與過去的業績相比如何,以及同一行業中其他公司的表現。這些估計表明,預計銷售將放緩,預計到2024年底,年化收入將下降4.9%。這表明,與去年40%的年增長率相比,已大幅下降。相比之下,我們的數據表明,在可預見的將來,同一行業的其他公司(包括分析師報道)的收入預計每年將增長15%。很明顯,預計Tango Therapeutics的收入表現將大大低於整個行業。
The Bottom Line
底線
The highlight for us was that the consensus reduced its estimated losses next year, perhaps suggesting Tango Therapeutics is moving incrementally towards profitability. Fortunately, they also upgraded their revenue estimates, and are forecasting revenues to grow slower than the wider market. Given that analysts appear to be expecting substantial improvement in the sales pipeline, now could be the right time to take another look at Tango Therapeutics.
對我們來說,亮點是,該共識減少了明年的預計虧損,這可能表明Tango Therapeutics正在逐步實現盈利。幸運的是,他們還上調了收入預期,並預測收入增長將低於整個市場。鑑於分析師似乎預計銷售渠道將取得實質性改善,現在可能是重新審視Tango Therapeutics的合適時機。
These earnings upgrades look like a sterling endorsement, but before diving in - you should know that we've spotted 4 potential warning signs with Tango Therapeutics, including dilutive stock issuance over the past year. For more information, you can click through to our platform to learn more about this and the 2 other warning signs we've identified .
這些收益上調看起來像是英鎊的支持,但在跳水之前,你應該知道,我們已經發現了Tango Therapeutics的4個潛在警告信號,包括過去一年的稀釋性股票發行。欲了解更多信息,您可以點擊進入我們的平台,詳細了解這一點以及我們發現的其他兩個警告信號。
Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are upgrading their estimates. So you may also wish to search this free list of stocks that insiders are buying.
當然,看到公司管理層將大量資金投資於股票與了解分析師是否在提高預期一樣有用。因此,您可能還希望搜索這份內部人士正在購買的免費股票清單。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。